The anthelmintic meclonazepam activates a schistosome transient receptor potential channel
Open Access
- 1 December 2023
- journal article
- research article
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 300 (1) , 105528
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (R01-AI145871)
- National Institutes of Health (T32 HL134643)
- National Institute of Allergy and Infectious Diseases (HHSN272201000005I)
- Texas Biomedical Research Institute
- Cardiovascular Center, Medical College of Wisconsin
- University College Dublin
This publication has 32 references indexed in Scilit:
- Synthesis, Biological Evaluation, and Structure–activity Relationship of Clonazepam, Meclonazepam, and 1,4‐Benzodiazepine Compounds with Schistosomicidal ActivityChemical Biology & Drug Design, 2012
- Genomes and geography: genomic insights into the evolution and phylogeography of the genus SchistosomaParasites & Vectors, 2011
- Praziquantel: its use in control of schistosomiasis in sub-Saharan Africa and current research needsParasitology, 2009
- The effects of 3-methylclonazepam on Schistosoma mansoni musculature are not mediated by benzodiazepine receptorsEuropean Journal of Pharmacology, 2009
- The unacknowledged impact of chronic schistosomiasisChronic Illness, 2008
- Praziquantel and the benzodiazepine Ro 11-3128 do not compete for the same binding sites in schistosomesParasitology, 2007
- Sex- and stage-related sensitivity of Schistosoma mansoni to in vivo and in vitro praziquantel treatmentInternational Journal for Parasitology, 2004
- Resistance following drug attenuation (Ro 11–3128 or oxamniquine) of earlySchistosoma mansoniinfections in miceParasitology, 1985
- Central effects in man of the novel schistosomicidal benzodiazepine meclonazepamEuropean Journal of Clinical Pharmacology, 1985
- Selective antagonists of benzodiazepinesNature, 1981